{
  "variants": [
    {
      "gene": "SNCA",
      "protein_change": "A30P",
      "variant_string_id": "SNCA A30P",
      "steps": [
        {
          "step": "1. Define Disease Mechanism",
          "judgment": "Yes",
          "reason": "The paper links SNCA mutations to familial PD and demonstrates their impact on dopamine synthesis genes (e.g., SR and TH) and transcriptional changes."
        },
        {
          "step": "2. Applicability of Assay Class",
          "judgment": "Yes",
          "reason": "Gene expression analysis (microarrays + qRT-PCR) directly addresses the role of SNCA in dopamine synthesis, aligning with the disease mechanism."
        },
        {
          "step": "3. Validity of Specific Assays",
          "sub_steps": [
            {
              "sub_step": "3a. Basic Controls and Replicates",
              "judgment": "Yes",
              "reason": "Wild-type and mutant (A30P, A53T) SNCA were compared, and qRT-PCR confirmed results, implying replicates."
            },
            {
              "sub_step": "3c. Variant Controls",
              "judgment": "Yes",
              "reason": "Wild-type (benign) and mutant (pathogenic) variants were used as controls."
            }
          ]
        },
        {
          "step": "4. Apply Evidence",
          "sub_steps": [
            {
              "sub_step": "4a. Statistical Analyses",
              "judgment": "No",
              "reason": "The paper does not explicitly report p-values, effect sizes, or OddsPath calculations."
            },
            {
              "sub_step": "4b. Control Variant Count",
              "judgment": "Max PS3_supporting",
              "reason": "Only 1 benign (wild-type) and 2 pathogenic (A30P, A53T) variants were used, totaling 3 controls (<10)."
            }
          ]
        }
      ],
      "strength": {
        "classification": "PS3_supporting",
        "reason": "Functional data shows wild-type SNCA downregulates dopamine synthesis genes, while mutants (A30P, A53T) do not, but statistical rigor is lacking."
      }
    },
    {
      "gene": "SNCA",
      "protein_change": "A53T",
      "variant_string_id": "SNCA A53T",
      "steps": [
        {
          "step": "1. Define Disease Mechanism",
          "judgment": "Yes",
          "reason": "Same as above; SNCA mutations disrupt dopamine synthesis and are linked to PD."
        },
        {
          "step": "2. Applicability of Assay Class",
          "judgment": "Yes",
          "reason": "Same as above; gene expression analysis aligns with the disease mechanism."
        },
        {
          "step": "3. Validity of Specific Assays",
          "sub_steps": [
            {
              "sub_step": "3a. Basic Controls and Replicates",
              "judgment": "Yes",
              "reason": "Same as above; wild-type and mutant SNCA were compared, and qRT-PCR confirmed results."
            },
            {
              "sub_step": "3c. Variant Controls",
              "judgment": "Yes",
              "reason": "Same as above; wild-type (benign) and mutant (pathogenic) variants were used as controls."
            }
          ]
        },
        {
          "step": "4. Apply Evidence",
          "sub_steps": [
            {
              "sub_step": "4a. Statistical Analyses",
              "judgment": "No",
              "reason": "Same as above; no explicit statistical tests or OddsPath calculations."
            },
            {
              "sub_step": "4b. Control Variant Count",
              "judgment": "Max PS3_supporting",
              "reason": "Same as above; only 1 benign (wild-type) and 2 pathogenic (A30P, A53T) variants were used, totaling 3 controls (<10)."
            }
          ]
        }
      ],
      "strength": {
        "classification": "PS3_supporting",
        "reason": "Functional data shows wild-type SNCA downregulates dopamine synthesis genes, while mutants (A30P, A53T) do not, but statistical rigor is lacking."
      }
    }
  ]
}